Vilon (Lys-Glu) is a thymus-derived dipeptide that modulates cytokine production and T-cell activation — the simplest thymic dipeptide in the Khavinson series and one with particularly well-documented immunomodulatory and anti-aging properties. As a two-amino acid peptide, Vilon combines the accessibility advantages of small peptide size (excellent bioavailability, intranasal delivery efficacy) with surprisingly potent effects on immune regulation, cellular proliferation control, and longevity pathways.

Vilon's immunological mechanism operates through multiple concurrent pathways. At the cytokine level, Vilon modulates the balance between pro-inflammatory and regulatory cytokine production — reducing excessive IL-1β, TNF-α, and IL-6 production while supporting IL-2 and regulated interferon responses. This cytokine normalization is the defining characteristic of Vilon among the thymic peptides: rather than purely stimulating immune activity, Vilon balances immune function, reducing the chronic low-grade pro-inflammatory cytokine dysregulation (inflammaging) that characterizes immune aging and drives multiple age-related pathologies.

At the cellular level, Vilon influences T-cell activation thresholds and proliferation dynamics. Vilon treatment increases the proportion of activated CD25+ T-cells (IL-2 receptor-expressing, actively proliferating T cells), enhances T-cell responsiveness to specific antigens, and improves the coordination between T-helper and T-cytotoxic subsets that governs adaptive immune response quality. These effects complement the thymic hormone activities of Thymosin Alpha-1 and Thymulin — Vilon's cytokine-level immunomodulation operates in parallel with the receptor-level thymic hormone activities.

Beyond immune effects, Vilon has attracted research interest for anti-aging properties that extend beyond the immune system. Vilon treatment in aging animal models has produced statistically significant lifespan extension in multiple experimental series — effects attributed to normalization of the chronic inflammatory signaling that drives multi-organ aging across tissues. The Khavinson group's lifespan extension data from Vilon parallels findings with Epithalon (the telomere-extending longevity peptide), suggesting that immune inflammatory normalization may be a significant pathway through which both peptides extend biological lifespan.

Vilon has also demonstrated effects on cellular proliferation regulation beyond the immune system — in particular, effects on cell cycle arrest and apoptotic pathway normalization in aging cells. This broader cellular regulation activity, combined with the immune modulation, positions Vilon as one of the more broadly bioactive anti-aging peptides in the Khavinson series, despite its extreme structural simplicity.

Protocol: 1mg/day for 10 consecutive days, intranasally or sublingually, 2–4 times per year. The smallest and most accessible thymic anti-aging peptide — effective as a standalone immune aging intervention and powerful in combination with the broader Crystagen/Thymosin Alpha-1/Thymogen thymic stack.